No Data
Shandong Lukang Pharmaceutical (600789.SH): Ezetimibe tablets have obtained the Pharmaceutical registration certificate.
On January 22nd, Gelonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced the receipt of the "Drug Registration Certificate" issued by the National Medical Products Administration for Ezetimibe Tablets. Ezetimibe reduces cholesterol levels in the blood by inhibiting the absorption of cholesterol in the small intestine, can attach to the brush border of the intestinal villi, inhibit cholesterol absorption, thereby reducing the transport of cholesterol from the small intestine to the liver, leading to a decrease in hepatic cholesterol stores and an increase in the clearance of cholesterol from the blood. This pharmaceutical can be used to treat primary hypercholesterolemia and can serve as an adjunct therapy beyond dietary control, used alone or in combination with other treatments.
Shandong Lukang Pharmaceutical (600789.SH): does not produce drugs related to the treatment of HIV infections.
Gelonghui, January 16 - Shandong Lukang Pharmaceutical (600789.SH) stated on the interactive platform that the company does not produce drugs related to the treatment of HIV virus infections.
Shandong Lukang Pharmaceutical (600789.SH): Currently, there have been no significant changes in the product structure and main Business.
Gelonghui, January 6: Shandong Lukang Pharmaceutical (600789.SH) announced that on January 2, 3, and 6, 2025, the cumulative closing price increase deviation value of the company's stocks exceeded 20% over two consecutive trading days. According to the relevant provisions of the Shanghai Stock Exchange trading rules, this is considered an abnormal fluctuation in stock trading. The company's main business includes the research and development, production, and sales of pharmaceutical products. The company's products mainly involve systemic anti-infective, cardiovascular, digestive system, endocrine, urology, respiratory system, and veterinary agricultural antibiotics, etc. Currently, both the product structure and main business are.
A-shares midday review: Chinext Price Index rises by 0.41%, flu Concept stocks are active, and the CSI Consumer 360 index sectors are experiencing a decline.
As of the midday break, the Shanghai Composite Index fell by 0.15% to 3206.75 points, the Shenzhen Component Index rose by 0.19%, and the Chinext Price Index increased by 0.41%.
A-share midday review: The Shanghai Composite Index fell by 0.46%. Resource stocks led the gains. The CSI Consumer 360 index underwent collective adjustment.
By midday, the Shanghai Composite Index fell by 0.46% to 3247.54 points, the Shenzhen Component Index declined by 0.23%, and the Chinext Price Index decreased by 0.28%.
The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.
According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
